Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-Center, Open Label Study Evaluating Clinical Efficacy, Safety, and Pharmacodynamic Effects of Quarfloxacin (CX-3543) in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

NCT00485966 is registered in ClinicalTrials.gov with Cylene Pharmaceuticals as lead sponsor.

NCT NCT00485966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00485966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-Center, Open Label Study Evaluating Clinical Efficacy, Safety, and Pharmacodynamic Effects of Quarfloxacin (CX-3543) in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Lead sponsor
Cylene Pharmaceuticals
Phase
Phase 2
Overall status
Withdrawn
Start date
June 30, 2007
Completion date
June 30, 2008
Enrollment
25 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell chronic lymphocytic leukemia